NCT00289029已完成4 期
Visipaque and Isovue in Cardiac Angiography in Renally Impaired Patients
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Increase in SCr at 48-72 hours post dose
研究概览
简要总结
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficiency undergoing cardiac angiography. Serum creatinine will be measured before and up to 48-72 hours after the administration of the contrast agent to evaluate renal function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Referred for cardiac angiography; with a documented predose eGFR of greater than or equal to 20 and less than 60 mL/min/1.73m2
排除标准
- •Unstable renal function; concurrent administration of nephrotoxic drugs, undergoing dialysis
结局指标
主要结局
Increase in SCr at 48-72 hours post dose
次要结局
- Decrease in eGFR at 48-72 hours post dose; occurrence of adverse events; effect on heart rate
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Patients With Renal Impairment Undergoing CTContrast Induced NephropathyNCT00292487Bracco Diagnostics, Inc150
已完成
4 期
Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)Contrast Induced NephropathyAcute Myocardial InfarctionNCT00827788Ospedale San Donato432
终止
4 期
Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic PatientsChronic Renal ImpairmentDiabetes MellitusNCT00782639Bracco Diagnostics, Inc23
已完成
4 期
Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus IopromideChronic Renal InsufficiencyCoronary AngiographyNCT00823628Seoul National University Bundang Hospital420
已完成
4 期
Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)Kidney DiseasesNCT00289614Bracco Diagnostics, Inc350